AVP Receptor V1a CRISPR/Cas9 KO Plasmid (h): sc-401691

Overview

AVPR1A encodes the arginine vasopressin receptor V1a, a rhodopsin-like GPCR that primarily couples to Gq/11 to activate phospholipase C, generating IP3/DAG signals that elevate intracellular Ca²⁺ and stimulate PKC-dependent transcriptional programs. V1a receptor signaling regulates vascular smooth muscle contraction, platelet responsiveness, hepatic glycogenolysis, and neuromodulatory circuits involved in social and stress-related behaviors. In cells, AVPR1A activity intersects with MAPK/ERK signaling, calcium-dependent gene regulation, and cytoskeletal remodeling that influence contractility and migration. Dysregulated vasopressin–V1a signaling has been investigated in cardiovascular and metabolic phenotypes and in neuropsychiatric trait associations, supporting mechanistic studies of receptor function across tissue contexts.

AVP Receptor V1a CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the AVPR1A gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the AVPR1A together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the AVPR1A open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish AVP Receptor V1a protein expression.

This CRISPR knockout system enables efficient generation of AVPR1A-deficient cell models for investigation of AVP Receptor V1a signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting AVPR1A exon(s) critical for AVP Receptor V1a function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple AVPR1A genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by AVP Receptor V1a CRISPR/Cas9 KO Plasmid (h) and AVP Receptor V1a CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the AVPR1A locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by AVP Receptor V1a HDR Plasmid (h) and AVP Receptor V1a HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by AVPR1A homology arms to support homology-directed repair at defined AVPR1A target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.